Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
The Lancet. Oncology|April 22, 2014
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion studyDavid S Hong, David Hui, Eduardo Bruera, et al.
Investigational New Drugs|November 4, 2014
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumorsGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Journal of Hematology & Oncology|January 1, 2020
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicineApostolia-Maria Tsimberidou, David S Hong, Jennifer J Wheler, et al.
Investigational New Drugs|November 27, 2012
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumorsDavid S Hong, Jennifer Hsing Choe, Aung Naing, et al.
Investigational New Drugs|October 18, 2014
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancerGerald S Falchook, Stacy Moulder, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiativeApostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.
Molecular Cancer Therapeutics|December 15, 2017
Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced CancersDivya Sakamuri, Isabella C Glitza, Sonia L Betancourt Cuellar, et al.
Plos One|March 4, 2014
FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitorsDenis L Jardim, Jennifer J Wheler, Kenneth Hess, et al.
Oncotarget|June 11, 2014
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathwayJennifer J Wheler, Stacy L Moulder, Aung Naing, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutationsFilip Janku, Jennifer J Wheler, Shannon N Westin, et al.
Pageof 8